Black checkmark with a sparkle and a curved line underneath on a white background.
Company

TriSalus Life Sciences, Inc.

Ticker
TLSI
Sector
Industry
Report date
November 10, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent quarterly results showed revenue growth and narrowing losses driven by increased sales of TriNav devices and improved gross margins. The company continues to expand its product portfolio and reimbursement coverage, while managing R&D expenses related to clinical trials.

Recent developments:
  • TriSalus reported an 11.3% increase in revenue for Q3 2026 compared to Q3 2025, primarily due to increased TriNav unit sales [N1].
  • Gross profit increased 14.9% year-over-year in Q3 2026, with gross margin rising to 86.2% from 83.5%, reflecting cost efficiencies and higher sales volume [N1].
  • Research and development expenses decreased 44.1% in Q3 2026 compared to prior year, mainly due to lower nelitolimod clinical trial costs [N1].
  • Sales and marketing expenses increased 56.9% in Q3 2026, reflecting investments in marketing and sales force expansion [N1].
  • Net loss narrowed by 18.1% year-over-year in Q3 2026 to $8.85 million [N1].
  • TriSalus obtained FDA 510(k) clearance for TriNav Advance in September 2026, expanding its product offerings [N4].
  • CMS established a new G-code reimbursement effective July 1, 2026, extending coverage for PEDD procedures in outpatient-based labs [N4].
Overview

TriSalus Life Sciences, Inc. develops and commercializes a proprietary drug delivery platform and immuno-oncology therapeutics targeting solid tumors such as liver and pancreatic cancers. Its core product line is the Pressure Enabled Drug Delivery (PEDD) infusion systems, marketed under the TriNav brand, designed to enhance therapeutic delivery by interventional radiologists. The company has expanded its TriNav portfolio with multiple device variants to address a broader range of anatomical complexities and embolization applications. TriSalus also pursues clinical development of nelitolimod, an immunotherapeutic agent delivered via PEDD technology, with ongoing investigator-initiated trials and plans for partnerships to advance clinical development. The company generates revenue primarily from sales of TriNav devices to hospitals and clinics, supported by permanent CMS reimbursement codes effective since 2024. TriSalus maintains a strong liquidity position and invests in sales and marketing to expand market penetration while managing R&D expenses related to clinical programs.

Executive summary

TriSalus Life Sciences, Inc. is a medical technology and immuno-oncology company focused on drug delivery systems for difficult-to-treat cancers, primarily through its PEDD infusion systems such as the TriNav product family. The company has FDA clearances and CMS reimbursement codes supporting commercial adoption. Recent financial results show revenue growth driven by increased device sales, improved gross margins, and reduced R&D expenses due to completion of certain clinical trials. The company maintains strong liquidity with over $41 million in cash as of September 30, 2026. Risks include reliance on third-party manufacturers, reimbursement uncertainties, and the challenges inherent in clinical development of its immuno-oncology drug candidate nelitolimod. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for TLSI

Bull case model:

TriSalus has demonstrated revenue growth and improved gross margins driven by increased sales of its TriNav devices, supported by favorable reimbursement codes from CMS. The expansion of its product portfolio with new device variants and FDA clearances broadens its addressable market. The initiation of the PROTECT registry study and ongoing investigator-initiated trials for nelitolimod indicate active clinical development and potential for future therapeutic combinations. Strong liquidity provides financial flexibility to support commercialization and R&D activities. The company's focus on difficult-to-treat cancers and innovative drug delivery technology positions it to capture market opportunities in interventional oncology.

Bear case model:

TriSalus faces risks from reliance on third-party manufacturers and suppliers, which could disrupt supply chains and delay clinical or commercial product availability. The reimbursement environment for TriNav devices is subject to change, and reductions in payment rates could adversely affect revenue. Clinical development of nelitolimod carries typical drug development risks including high costs, regulatory uncertainty, and the need for partnerships. Competition for skilled personnel in sales and scientific roles is intense, potentially impacting execution. Collaborations and strategic alliances may not materialize or deliver anticipated benefits, adding operational complexity and risk.

Moat:

TriSalus' moat is anchored in its proprietary PEDD infusion technology platform and the TriNav product family, which offer differentiated capabilities for delivering therapeutics to solid tumors. The company has secured FDA clearances and permanent CMS reimbursement codes, facilitating adoption in hospital and outpatient settings. Its focus on difficult-to-treat cancers and integration of drug delivery with immuno-oncology therapeutics creates a specialized niche. However, the moat is challenged by competition from other medical device companies and the need to maintain reimbursement and regulatory approvals. The company's ability to expand its product portfolio and clinical pipeline, along with building a skilled sales force, supports its competitive positioning.

Risks overview
Risks summary
The most significant risks for TriSalus include supply chain dependencies, reimbursement uncertainties, and the challenges inherent in advancing clinical-stage therapeutics, all of which could materially affect business performance.
Risks details:

• Supply Chain and Manufacturing Risks: Dependence on third-party manufacturers and suppliers for drug candidate and device production introduces risks of delays, quality issues, regulatory non-compliance, and potential interruptions that could adversely affect development and commercialization timelines.
• Reimbursement and Pricing Risks: TriSalus relies on CMS reimbursement codes for TriNav devices; changes or reductions in reimbursement rates or coverage could materially impact revenue and profitability.
• Clinical Development Risks: Nelitolimod is in early-stage clinical trials with inherent risks including trial costs, uncertain outcomes, regulatory approval challenges, and the need for external partnerships to advance development.
• Talent Acquisition and Retention Risks: The company operates in a competitive environment for skilled sales, scientific, and managerial personnel; failure to attract or retain key employees could impair growth and execution.
• Collaborations and Strategic Alliances Risks: Potential collaborations and licensing arrangements may be complex, may not be secured on acceptable terms, and could result in conflicts or termination, affecting product development and commercialization.

FINAL FORECAST FOR TLSI

Final take one line
TriSalus Life Sciences exhibits very high visibility with detailed disclosures on its innovative drug delivery platform, expanding product portfolio, reimbursement support, and clinical development progress, balanced by typical industry risks.
Final take 12 to 24 month view

Business trends: Growth in TriNav device sales supported by FDA clearances and CMS reimbursement codes; ongoing clinical development of nelitolimod with investigator-initiated trials.
Execution milestones: Expansion of TriNav product family including TriNav Advance clearance; establishment of new reimbursement codes; continued clinical trial progress and pursuit of partnerships for nelitolimod.
Key risks: Dependence on third-party manufacturing and supply chains; reimbursement rate uncertainties; clinical development and regulatory approval challenges; competition for skilled personnel; complexities in collaborations and alliances.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • TriSalus Life Sciences, Inc. develops and commercializes a drug delivery technology platform and an immuno-oncology therapeutic targeting difficult-to-treat liver and pancreatic cancers [S1].
  • The company markets Pressure Enabled Drug Delivery (PEDD) infusion systems, including the TriNav product family, designed to optimize therapeutic delivery for hepatocellular carcinoma, pancreatic cancer, and other solid liver tumors [S1].
  • TriNav products include TriNav, TriNav FLX, TriNav XP, TriNav LV, TriGuide Guiding Catheter, and TriNav Advance, with the latter receiving FDA 510(k) clearance in September 2026 [S1].
  • TriNav devices have permanent HCPCS reimbursement codes from CMS effective from 2024 and 2025, with additional G-code reimbursement effective July 1, 2026, facilitating coverage in hospital outpatient departments, ambulatory surgical centers, and outpatient-based labs [S1].
  • The company initiated a registry study called PROTECT for thyroid disease embolization, estimating an incremental $400 million market opportunity with reimbursement under existing HCPCS codes [S1].
  • TriSalus acquired the immuno-oncology drug nelitolimod in 2020 and conducted Phase I and Phase Ib clinical trials; ongoing investigator-initiated trials are supported but the company seeks partners for further development due to capital costs [S1].
  • Revenue is primarily generated from sales of PEDD infusion systems, principally TriNav, to hospitals and clinics with direct sales [S1].
  • For the three months ended September 30, 2026, revenue increased 11.3% year-over-year to $12.9 million, driven by increased TriNav unit sales [S2].
  • Gross margin improved to 86.2% in Q3 2026 from 83.5% in Q3 2025, due to higher sales volume and reduced cost per unit [S2].
  • Research and development expenses decreased 44.1% year-over-year in Q3 2026, primarily due to lower clinical trial expenses related to nelitolimod [S2].
  • Sales and marketing expenses increased 56.9% year-over-year in Q3 2026, reflecting investment in marketing and sales force expansion [S2].
  • General and administrative expenses decreased 20.4% year-over-year in Q3 2026 [S2].
  • Net loss for Q3 2026 was $8.85 million, an 18.1% improvement compared to Q3 2025 [S2].
  • As of September 30, 2026, TriSalus held $41.1 million in cash and cash equivalents, with a current ratio of 4.22 and a cash ratio of 3.15, indicating strong liquidity [S2].
  • The company faces risks related to reliance on third-party manufacturers and suppliers for drug candidate production, potential supply chain disruptions, and regulatory compliance challenges [S1].
  • TriSalus depends on attracting and retaining skilled personnel, particularly in sales and scientific roles, in a competitive industry environment [S1].
  • Reimbursement rates and coverage for TriNav products by CMS and other payers are critical to revenue generation and may change, impacting financial results [S1].
  • The clinical development of nelitolimod carries typical drug development risks including trial costs, regulatory approval uncertainty, and the need for partnerships [S1].
  • The company’s business model includes potential collaborations, licensing, and strategic alliances, which may be complex and carry risks of conflicts or termination [S1].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-05 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-10 | www.nasdaq.com | TriSalus Life Sciences, Inc. Q3 Loss Narrows | https://www.nasdaq.com/articles/trisalus-life-sciences-inc-q3-loss-narrows
  • N2 | 2026-11-04 | www.nasdaq.com | Insulet (PODD) Q3 Earnings and Revenues Surpass Estimates | https://www.nasdaq.com/articles/insulet-podd-q3-earnings-and-revenues-surpass-estimates
  • N3 | 2026-10-29 | www.nasdaq.com | Verano Holdings Corp. (VRNO) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/verano-holdings-corp-vrno-reports-q3-loss-lags-revenue-estimates
  • N4 | 2026-08-07 | www.nasdaq.com | TriSalus Life Sciences Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/trisalus-life-sciences-q2-earnings-call-highlights
  • N5 | 2026-05-14 | www.nasdaq.com | TriSalus (TLSI) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/trisalus-tlsi-q1-2026-earnings-transcript
  • N6 | 2026-05-13 | www.nasdaq.com | TriSalus Life Sciences Q1 Earnings Call Highlights | https://www.nasdaq.com/articles/trisalus-life-sciences-q1-earnings-call-highlights
  • N7 | 2026-05-12 | www.nasdaq.com | TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/trisalus-life-sciences-inc-tlsi-reports-q1-loss-lags-revenue-estimates
  • N8 | 2026-05-07 | www.nasdaq.com | VAREX IMAGING (VREX) Q2 Earnings and Revenues Miss Estimates | https://www.nasdaq.com/articles/varex-imaging-vrex-q2-earnings-and-revenues-miss-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine